What’s the Future of Gene Editing?
The gene editing landscape is expanding rapidly through next-generation CRISPR tools and significant projected market growth through 2028.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The field of genome editing is experiencing a period of substantial growth and technical evolution. According to reporting from openPR.com, the genome editing market size is projected to expand from a value of US$ 5,199.40 million in 2021 to US$ 16,986.69 million by 2028. This financial trajectory coincides with the development of new capabilities in the sector, specifically regarding the deployment of next-generation CRISPR tools. These advancements are described as transforming both the broader practice of gene editing and the specific application of gene therapy, as detailed in coverage by News-Medical. Various media outlets are focusing on different dimensions of this scientific shift. News-Medical emphasizes the transformative nature of next-generation tools for therapy and editing, while Quanta Magazine is examining the broader conceptual question of what the future of gene editing actually holds.
Beyond medical applications, the scope of this technology extends into the agricultural and nutritional sectors. Food Tank has provided specific explanatory coverage on CRISPR, indicating that the technology's reach encompasses food systems and production methods alongside clinical healthcare developments. To understand the current state of the industry, it is necessary to recognize that CRISPR is no longer a singular tool but a foundation for a wider array of next-generation instruments. The shift from the 2021 market valuation to the 2028 projection highlights a massive scale-up in commercial interest and investment. This context suggests that the transition from theoretical research to applied therapy and agricultural implementation is driving the economic expansion noted in the financial data. The integration of these tools into gene therapy suggests a move toward more precise medical interventions.
Future developments will likely center on the continued deployment of these next-generation CRISPR tools across the diverse fields identified in the coverage. Observers can expect further updates on the market's progress toward the US$ 16,986.69 million target by 2028. Additionally, the trajectory of gene therapy and the application of CRISPR within the food sector, as highlighted by Food Tank, will be key areas of focus. The ongoing evolution of these tools will determine how the future of gene editing unfolds across both human health and global food systems.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 109d ago.
Quick answers
What is the projected market size for genome editing by 2028?
The market size is projected to grow to US$ 16,986.69 million by 2028, up from US$ 5,199.40 million in 2021.
How are next-generation CRISPR tools impacting the field?
According to News-Medical, these tools are transforming the processes of gene editing and gene therapy.
Is CRISPR being used for things other than human medicine?
Yes, Food Tank provides coverage explaining the use of CRISPR in the context of food.
Coverage (4)
- Genome Editing Market Size to Expand from US$ 5,199.40 Million in 2021 to US$ 16,986.69 Million by 2028 openPR.com · 156d ago
- Next-Generation CRISPR Tools Transform Gene Editing And Gene Therapy News-Medical · 156d ago
- Food Tank Explains: CRISPR Food Tank · 156d ago
- What’s the Future of Gene Editing? Quanta Magazine · 156d ago
Topics
Related trends
Occasional male cannabis users experience stronger effects than women - News-Medical
A UCLA study found that men who use cannabis occasionally feel stronger effects than women with similar use habits, even when blood THC levels are about the same.
Obesity drugs may help protect memory and cognitive abilities - News-Medical
A major review of nearly 200 preclinical studies and major clinical trials finds that GLP-1 obesity drugs may protect the brain, but randomized trials have not shown a clear cognitive benefit.
Epileptic seizures nearly vanish after people receive experimental gene therapy in their brains
Experimental brain gene therapy cuts drug-resistant epilepsy seizures by over ninety percent in human trials.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
An AI Agent Injected Drugs Into a Live Mouse’s Brain
An autonomous AI agent has performed a gene therapy brain injection on a live mouse after a refusal by an earlier model.
Hospital patients treated by female physicians have better outcomes - News-Medical
A large-scale study of nearly one million patients suggests that female physicians are linked to lower mortality and readmission rates for hospital patients.